Indivior Pharmaceuticals, Inc.·4

Mar 5, 3:59 PM ET

Heidbreder Christian 4

4 · Indivior Pharmaceuticals, Inc. · Filed Mar 5, 2026

Insider Transaction Report

Form 4
Period: 2026-03-03
Heidbreder Christian
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1][F2]
    2026-03-03+101,544292,306 total
  • Tax Payment

    Common Stock

    [F3]
    2026-03-03$31.98/sh45,797$1,464,588246,509 total
  • Exercise/Conversion

    Performance Stock Units

    [F2][F1]
    2026-03-03132,5650 total
    Exercise: $0.00From: 2026-03-03Common Stock (132,565 underlying)
Footnotes (3)
  • [F1]Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 101,544 shares vested out of the 132,565 target amount.
  • [F2]Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.
  • [F3]Shares used to satisfy tax withholding obligations associated with the vesting of performance stock units on March 3, 2026.
Signature
/s/Alice Givens, Power of Attorney|2026-03-05

Documents

1 file
  • 4
    wk-form4_1772744339.xmlPrimary

    FORM 4